ClinicalTrials.gg
CompletedNCT01435655Updated Sep 9, 2015Results posted

The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin

A Phase 3 interventional study of tafamidis in Transthyretin Familial Amyloid Polyneuropathy, sponsored by Pfizer. Completed at 2 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-09.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Study summary

Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.

02

Conditions studied

  • Transthyretin Familial Amyloid Polyneuropathy
03

In context

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

This study's enrollment of 10 is below the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.

Browse Amyloid Neuropathies, Familial studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.
  • Subject had amyloid documented by in accordance with institutional site standard of care.

Exclusion criteria

Exclusion Criteria:

  • Primary amyloidosis and secondary amyloidosis.
  • History of liver transplant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    open

    tafamidis

    Drug: tafamidis

Interventions

  • tafamidis meglumine 20 mg QD

    Also known as: tafamidis meglumine

06

What researchers measure

Primary outcomes

  1. Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay

    TTR tetramer level for each plasma sample was assessed using a validated immunoturbidimetric assay before and after urea denaturation. The Fraction of Initial (FOI) tetramer concentration is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer average concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI. A patient who has the "TTR stabilization" is defined as the patient whose percent stabilization is equal to or more than 32%.

    Time frame: 8 weeks

Secondary outcomes

  1. Change From Baseline in Neuropathy Impairment Score (NIS); NIS (Total), NIS-LL (Lower Limb) and NIS-UL (Upper Limb) at Week 26, Week 52 and Week 78

    The NIS provides a total body single score of neuropathic deficits (score range: 0-122, higher score = more deficit), comprising subset scores for cranial nerves, muscle weakness, reflexes, and sensation (based on mean of 2 scores in 1 week period; each item scored separately for left and right). The NIS-LL is a subscale that provides a score for the lower limbs functions (muscle weakness, reflexes and sensation in great toe) and has a score range of 0-44 (higher score = more deficit). The NIS-UL is a subscale that provides a score for the upper body functions (muscle weakness \[including cranial nerves\], reflexes and sensation in finger) and has a score range of 0-78 (higher score = more deficit). The components for cranial nerves and muscle weakness are scored from 0 (Normal) to 4 (Paralysis), and those for reflexes and sensation from 0 (Normal) to 2 (Absent). For all items, higher scores indicate greater impairment.

    Time frame: Baseline, Week 26, Week 52, Week 78

  2. Change From Baseline in Scores of the Total Quality of Life (TQOL) and 5 Domains as Measured by the Norfolk QOL - Diabetic Neuropathy (Norfolk QOL-DN) at Week 26, Week 52 and Week 78.

    Norfolk QOL-DN is a 35-item participant-rated questionnaire. It consists of 5 domains: Physical Functioning/Large Fiber \[score range: -4 - 56\] , Activities of Daily Living (ADL) \[0 - 20\], Symptoms \[0 - 32\], Small Fiber \[0 - 16\] and Autonomic \[0 - 12\]. Total of quality of life (TQOL) score is the sum of all five domains with a range of -4 to 136 (Pfizer Data Standards). Higher scores on each item of the Norfolk QOL-DN TQOL indicate worse quality of life.

    Time frame: Baseline, Week 26, Week 52, Week 78

  3. Change From Baseline in Summated 7 Nerve Tests Normal Deviate Score (∑ 7 NTs Nds) as Measured by Nerve Conduction Studies (NCS), Vibration Detection Threshold (VDT) and Heart Rate Response to Deep Breathing (HRDB) at Week 26, Week 52, and Week 78

    The Σ7 NTs nds measures primarily large-fiber function. It is a composite score derived from five NCS attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with VDT obtained in great toes by Quantitative Sensory Testing (QST), and HRDB value. It is defined as 7 times the mean of non-missing values of, the five normal deviates of NCS, HRDB, and average normal deviate for VDT of toes. Score was determined through reference to normal values for age, sex, height and abnormalities scored. Total score range is approximately -26 to 26, where higher score=worse nerve function.

    Time frame: Baseline, Week 26, Week 52, Week 78

  4. Change From Baseline in Summated 3 Nerve Tests Small Fiber Normal Deviate Score (∑ 3 NTSF Nds) as Measured by Cooling and Heat Pain Thresholds by QST and HRDB at Week 26, Week 52 and Week 78

    The Σ3 NTSF nds measures small-fiber function. It is a composite score defined as 3 times the mean of non-missing values of normal deviates of cooling threshold for lower limbs, heat pain intermediate response for lower limbs, and HRDB. The total score range is approximately -11.2 to 11.2, with a higher score demonstrating worse nerve function.

    Time frame: Baseline, Week 26, Week 52, Week 78

  5. Change From Baseline in Modified Body Mass Index (mBMI) at Week 8, Week 26, Week 52 and End of Study

    The mBMI was calculated by multiplying the BMI (the weight in kilograms divided by the square of the height in meters) by serum albumin level (gram/liter). Change in mBMI was calculated as the mBMI at the given week minus the Baseline mBMI.

    Time frame: Baseline, Week 8, Week 26, Week 52, End of Study

  6. Change From Baseline in Ambulatory Status at Week 26, Week 52 and Week 78

    Ambulatory status was evaluated using walking ability scale in polyneuropathy disability score. The ambulatory status was evaluated as: 0=Good, 1=Sensory disturbances in the feet but able to walk without difficulty, 2=Some difficulties with walking but can walk without aid, 3a=Able to walk with 1 stick or crutch, 3b=Able to walk with 2 sticks or crutches, 4=Not ambulatory, confined to a wheelchair or bedridden.

    Time frame: Baseline, Week 26, Week 52, Week 78

  7. Number of Participants With Transthyretin (TTR) Stabilization at Week 26, Week 52, and Week 78 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay

    TTR tetramer was assessed using a validated immunoturbidimetric assay. The TTR tetramer level for each plasma sample was measured before and after urea denaturation. The Fraction of Initial (FOI) tetramer concentration is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI. A patient who has the "TTR stabilization" is defined as the patient whose percent stabilization is equal to or more than 32%.

    Time frame: Baseline, Week 26, Week 52, Week 78

Other outcomes

  1. Plasma Concentration of Tafamidis at Week 8, Week 26, Week 52 and Week 78

    Mean plasma concentration of tafamidis at 3 hours after administration

    Time frame: Week 8, Week 26, Week 52, Week 78

07

Results

Posted Sep 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneTafamidis 20 mg
Started10
Completed7
Not completed3
Withdrew: Death2
Withdrew: Other1

Outcome measures

PrimaryNumber of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay

TTR tetramer level for each plasma sample was assessed using a validated immunoturbidimetric assay before and after urea denaturation. The Fraction of Initial (FOI) tetramer concentration is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer average concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI. A patient who has the "TTR stabilization" is defined as the patient whose percent stabilization is equal to or more than 32%.

Time frame:
8 weeks
Reported as:
Number · Participants
Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay
ParticipantsTafamidis 20 mg
Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay10
SecondaryChange From Baseline in Neuropathy Impairment Score (NIS); NIS (Total), NIS-LL (Lower Limb) and NIS-UL (Upper Limb) at Week 26, Week 52 and Week 78

The NIS provides a total body single score of neuropathic deficits (score range: 0-122, higher score = more deficit), comprising subset scores for cranial nerves, muscle weakness, reflexes, and sensation (based on mean of 2 scores in 1 week period; each item scored separately for left and right). The NIS-LL is a subscale that provides a score for the lower limbs functions (muscle weakness, reflexes and sensation in great toe) and has a score range of 0-44 (higher score = more deficit). The NIS-UL is a subscale that provides a score for the upper body functions (muscle weakness \[including cranial nerves\], reflexes and sensation in finger) and has a score range of 0-78 (higher score = more deficit). The components for cranial nerves and muscle weakness are scored from 0 (Normal) to 4 (Paralysis), and those for reflexes and sensation from 0 (Normal) to 2 (Absent). For all items, higher scores indicate greater impairment.

Time frame:
Baseline, Week 26, Week 52, Week 78
Reported as:
Mean · Units on a scale
Change From Baseline in Neuropathy Impairment Score (NIS); NIS (Total), NIS-LL (Lower Limb) and NIS-UL (Upper Limb) at Week 26, Week 52 and Week 78
Units on a scaleTafamidis 20 mg
NIS-Total: Baseline (n=10)31.03 ± 26.260
NIS-Total: Change at Week 26 (n=10)4.37 ± 9.408
NIS-Total: Change at Week 52 (n=10)8.30 ± 8.326
NIS-Total: Change at Week 78 (n=8)9.90 ± 12.584
NIS-LL: Baseline (n=10)16.99 ± 13.143
NIS-LL: Change at Week 26 (n=10)2.06 ± 5.565
NIS-LL: Change at Week 52 (n=10)3.62 ± 4.374
NIS-LL: Change at Week 78 (n=8)3.30 ± 4.739
NIS-UL: Baseline (n=10)14.03 ± 13.716
NIS-UL: Change at Week 26 (n=10)2.31 ± 4.066
NIS-UL: Change at Week 52 (n=10)4.68 ± 5.103
NIS-UL: Change at Week 78 (n=8)6.59 ± 8.724
SecondaryChange From Baseline in Scores of the Total Quality of Life (TQOL) and 5 Domains as Measured by the Norfolk QOL - Diabetic Neuropathy (Norfolk QOL-DN) at Week 26, Week 52 and Week 78.

Norfolk QOL-DN is a 35-item participant-rated questionnaire. It consists of 5 domains: Physical Functioning/Large Fiber \[score range: -4 - 56\] , Activities of Daily Living (ADL) \[0 - 20\], Symptoms \[0 - 32\], Small Fiber \[0 - 16\] and Autonomic \[0 - 12\]. Total of quality of life (TQOL) score is the sum of all five domains with a range of -4 to 136 (Pfizer Data Standards). Higher scores on each item of the Norfolk QOL-DN TQOL indicate worse quality of life.

Time frame:
Baseline, Week 26, Week 52, Week 78
Reported as:
Mean · Units on a scale
Change From Baseline in Scores of the Total Quality of Life (TQOL) and 5 Domains as Measured by the Norfolk QOL - Diabetic Neuropathy (Norfolk QOL-DN) at Week 26, Week 52 and Week 78.
Units on a scaleTafamidis 20 mg
TQOL: Baseline (n=10)52.9 ± 32.76
TQOL: Change at Week 26 (n=10)11.8 ± 20.01
TQOL: Change at Week 52 (n=10)9.1 ± 12.49
TQOL: Change at Week 78 (n=8)10.8 ± 13.69
Physical Functioning: Baseline (n=10)25.6 ± 15.28
Physical Functioning: Change at Week 26 (n=10)4.8 ± 10.02
Physical Functioning: Change at Week 52 (n=10)2.2 ± 8.87
Physical Functioning: Change at Week 78 (n=8)4.1 ± 7.83
ADL: Baseline (n=10)8.5 ± 7.63
ADL: Change at Week 26 (n=10)1.2 ± 3.61
ADL: Change at Week 52 (n=10)0.8 ± 3.52
ADL: Change at Week 78 (n=8)0.6 ± 2.33
Symptoms: Baseline (n=10)8.5 ± 5.34
Symptoms: Change at Week 26 (n=10)2.6 ± 3.47
Symptoms: Change at Week 52 (n=10)4.0 ± 5.73
Symptoms: Change at Week 78 (n=8)3.1 ± 3.94
Small Fiber: Baseline (n=10)6.3 ± 5.31
Small Fiber: Change at Week 26 (n=10)1.9 ± 4.25
Small Fiber: Change at Week 52 (n=10)1.6 ± 2.32
Small Fiber: Change at Week 78 (n=8)2.1 ± 3.76
Autonomic: Baseline (n=10)4.0 ± 3.06
Autonomic: Change at Week 26 (n=10)1.3 ± 1.42
Autonomic: Change at Week 52 (n=10)0.5 ± 1.43
Autonomic: Change at Week 78 (n=8)0.8 ± 1.91
SecondaryChange From Baseline in Summated 7 Nerve Tests Normal Deviate Score (∑ 7 NTs Nds) as Measured by Nerve Conduction Studies (NCS), Vibration Detection Threshold (VDT) and Heart Rate Response to Deep Breathing (HRDB) at Week 26, Week 52, and Week 78

The Σ7 NTs nds measures primarily large-fiber function. It is a composite score derived from five NCS attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with VDT obtained in great toes by Quantitative Sensory Testing (QST), and HRDB value. It is defined as 7 times the mean of non-missing values of, the five normal deviates of NCS, HRDB, and average normal deviate for VDT of toes. Score was determined through reference to normal values for age, sex, height and abnormalities scored. Total score range is approximately -26 to 26, where higher score=worse nerve function.

Time frame:
Baseline, Week 26, Week 52, Week 78
Reported as:
Mean · Units on a scale
Change From Baseline in Summated 7 Nerve Tests Normal Deviate Score (∑ 7 NTs Nds) as Measured by Nerve Conduction Studies (NCS), Vibration Detection Threshold (VDT) and Heart Rate Response to Deep Breathing (HRDB) at Week 26, Week 52, and Week 78
Units on a scaleTafamidis 20 mg
Baseline (n=10)8.33 ± 5.574
Change at Week 26 (n=10)0.55 ± 2.657
Change at Week 52 (n-=10)1.04 ± 2.992
Change at Week 78 (n=8)1.92 ± 5.129
SecondaryChange From Baseline in Summated 3 Nerve Tests Small Fiber Normal Deviate Score (∑ 3 NTSF Nds) as Measured by Cooling and Heat Pain Thresholds by QST and HRDB at Week 26, Week 52 and Week 78

The Σ3 NTSF nds measures small-fiber function. It is a composite score defined as 3 times the mean of non-missing values of normal deviates of cooling threshold for lower limbs, heat pain intermediate response for lower limbs, and HRDB. The total score range is approximately -11.2 to 11.2, with a higher score demonstrating worse nerve function.

Time frame:
Baseline, Week 26, Week 52, Week 78
Reported as:
Mean · Units on a scale
Change From Baseline in Summated 3 Nerve Tests Small Fiber Normal Deviate Score (∑ 3 NTSF Nds) as Measured by Cooling and Heat Pain Thresholds by QST and HRDB at Week 26, Week 52 and Week 78
Units on a scaleTafamidis 20 mg
Baseline (n=10)6.39 ± 3.160
Change at Week 26 (n=10)0.16 ± 1.619
Change at Week 52 (n=10)-0.13 ± 1.334
Change at Week 78 (n=8)0.40 ± 1.985
SecondaryChange From Baseline in Modified Body Mass Index (mBMI) at Week 8, Week 26, Week 52 and End of Study

The mBMI was calculated by multiplying the BMI (the weight in kilograms divided by the square of the height in meters) by serum albumin level (gram/liter). Change in mBMI was calculated as the mBMI at the given week minus the Baseline mBMI.

Time frame:
Baseline, Week 8, Week 26, Week 52, End of Study
Reported as:
Mean · (kilogram/square meter)*(gram/liter)
Change From Baseline in Modified Body Mass Index (mBMI) at Week 8, Week 26, Week 52 and End of Study
(kilogram/square meter)*(gram/liter)Tafamidis 20 mg
Baseline (n=10)805.70 ± 193.378
Change at Week 8 (n=10)74.86 ± 88.706
Change at Week 26 (n=10)26.61 ± 61.862
Change at Week 52 (n=10)64.86 ± 80.016
End of Study (n=7)53.65 ± 81.386
SecondaryChange From Baseline in Ambulatory Status at Week 26, Week 52 and Week 78

Ambulatory status was evaluated using walking ability scale in polyneuropathy disability score. The ambulatory status was evaluated as: 0=Good, 1=Sensory disturbances in the feet but able to walk without difficulty, 2=Some difficulties with walking but can walk without aid, 3a=Able to walk with 1 stick or crutch, 3b=Able to walk with 2 sticks or crutches, 4=Not ambulatory, confined to a wheelchair or bedridden.

Time frame:
Baseline, Week 26, Week 52, Week 78
Reported as:
Number · Participants
Change From Baseline in Ambulatory Status at Week 26, Week 52 and Week 78
ParticipantsTafamidis 20 mg
Baseline (n=10): Status 00
Baseline (n=10): Status 13
Baseline (n=10): Status 24
Baseline (n=10): Status 3a2
Baseline (n=10): Status 3b1
Baseline (n=10): Status 40
Week 26 (n=10): Status 01
Week 26 (n=10): Status 12
Week 26 (n=10): Status 23
Week 26 (n=10): Status 3a2
Week 26 (n=10): Status 3b2
Week 26 (n=10): Status 40
Week 52 (n=10): Status 01
Week 52 (n=10): Status 11
Week 52 (n=10): Status 24
Week 52 (n=10): Status 3a2
Week 52 (n=10): Status 3b2
Week 52 (n=10): Status 40
Week 78 (n=8): Status 01
Week 78 (n=8): Status 11
Week 78 (n=8): Status 22
Week 78 (n=8): Status 3a2
Week 78 (n=8): Status 3b2
Week 78 (n=8): Status 40
SecondaryNumber of Participants With Transthyretin (TTR) Stabilization at Week 26, Week 52, and Week 78 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay

TTR tetramer was assessed using a validated immunoturbidimetric assay. The TTR tetramer level for each plasma sample was measured before and after urea denaturation. The Fraction of Initial (FOI) tetramer concentration is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI. A patient who has the "TTR stabilization" is defined as the patient whose percent stabilization is equal to or more than 32%.

Time frame:
Baseline, Week 26, Week 52, Week 78
Reported as:
Number · Participants
Number of Participants With Transthyretin (TTR) Stabilization at Week 26, Week 52, and Week 78 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay
ParticipantsTafamidis 20 mg
Week 2610
Week 529
Week 788
Other pre-specifiedPlasma Concentration of Tafamidis at Week 8, Week 26, Week 52 and Week 78

Mean plasma concentration of tafamidis at 3 hours after administration

Time frame:
Week 8, Week 26, Week 52, Week 78
Reported as:
Mean · ng/mL
Plasma Concentration of Tafamidis at Week 8, Week 26, Week 52 and Week 78
ng/mLTafamidis 20 mg
Week 8 (n=10)2773.0 ± 1777.71
Week 26 (n=10)2739.0 ± 1893.25
Week 52 (n=10)2829.0 ± 2315.58
Week 78 (n=8)3655.0 ± 2268.08

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tafamidis 20 mg—7/10 (70%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventTafamidis 20 mg
Pneumonia bacterialInfections and infestations3/10
Atrioventricular block second degreeCardiac disorders1/10
Sick sinus syndromeCardiac disorders1/10
IleusGastrointestinal disorders1/10
Sudden deathGeneral disorders1/10
PyelonephritisInfections and infestations1/10
Burns third degreeInjury, poisoning and procedural complications1/10
Decreased appetiteMetabolism and nutrition disorders1/10
Completed suicidePsychiatric disorders1/10
Most frequent other events
Showing 10 of 57
Most frequent other events
EventTafamidis 20 mg
NasopharyngitisInfections and infestations5/10
Muscular weaknessMusculoskeletal and connective tissue disorders5/10
Thermal burnInjury, poisoning and procedural complications3/10
CataractEye disorders2/10
Vitreous opacitiesEye disorders2/10
NauseaGastrointestinal disorders2/10
VomitingGastrointestinal disorders2/10
Muscle spasmsMusculoskeletal and connective tissue disorders2/10
MyalgiaMusculoskeletal and connective tissue disorders2/10
InsomniaPsychiatric disorders2/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tafamidis 20 mg
Mean60.1 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Tafamidis 20 mg
Female3
Male7
08

Study locations

2 sites
  • Kumamoto University Hospital/Department of Neurology
    Kumamoto-shi, Kumamoto 860-8556, Japan
  • Shinshu University Hospital/Department of Medicine (Neurology and Reumatology)
    Matsumoto-shi, Nagano 390-8621, Japan
09

References and documents

Publications

  • Huber P, Flynn A, Sultan MB, Li H, Rill D, Ebede B, Gundapaneni B, Schwartz JH. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy. Amyloid. 2019 Dec;26(4):203-209. doi: 10.1080/13506129.2019.1643714. Epub 2019 Jul 27. PubMed 31353964 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2011
First posted
Sep 16, 2011
Start
Nov 2011
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Sep 9, 2015
Last update
Sep 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01435655
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 16, 2011
Start date
Nov 2011
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Sep 9, 2015
Last update
Sep 9, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion